Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR)

Jiménez, Carmen Tenorio; Martínez-Ramírez, M.J.; Tercero-Lozano, Mercedes; Arraiza-Irigoyen, Carmen; Castillo-Codes, Isabel Del; Olza, Josune; Plaza‐Díaz, Julio; Fontana, Luis; Migueles, Jairo H; Olivares, Mónica; Gil, Ángel; Gómez-Llorente, Carolina

doi:10.1186/s12906-018-2371-x

Cited by 43 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We performed a randomized, double-blind, crossover, placebo-controlled, single-center trial in patients with a new diagnosis of MetS, according to the criteria of the International Diabetes Federation (IDF). The complete study design including sample size, randomization, and the trial protocol have been previously published [17] and registered at as NCT02972567. The study was conducted in agreement with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.…”

Section: Methodsmentioning

confidence: 99%

“…Sample size was calculated based on the range and median value of lipopolysaccharide (LPS) and assuming a power of 80% and a significant level of 5% [17]. In brief, a total of 53 out of 60 adult patients were recruited at the Endocrinology and Nutrition Clinical Management Unit, University Hospital of Jaén (Jaén, Spain) by qualified personnel.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

Previous studies have reported that probiotics may improve clinical and inflammatory parameters in patients with obesity and metabolic syndrome (MetS). Lactobacillus (L.) reuteri V3401 has shown promising results on the components of MetS in animal studies. We aimed to evaluate the effects of L. reuteri V3401 together with healthy lifestyle recommendations on adult patients with MetS. Methods: We carried out a randomized, crossover, placebo-controlled, single-center trial in which we included 53 adult patients newly diagnosed with MetS. Patients were block randomly allocated by body mass index (BMI) and sex to receive a capsule containing either the probiotic L. reuteri V3401 (5 × 109 colony-forming units) or a placebo once daily for 12 weeks. Anthropometric variables, biochemical and inflammatory biomarkers, as well as the gastrointestinal microbiome composition were determined. Results: There were no differences between groups in the clinical characteristics of MetS. However, we found that interleukin-6 (IL-6) and soluble vascular cell adhesion molecule 1 (sVCAM-1) diminished by effect of the treatment with L. reuteri V3401. Analysis of the gastrointestinal microbiome revealed a rise in the proportion of Verrucomicrobia. Conclusions: Consumption of L. reuteri V3401 improved selected inflammatory parameters and modified the gastrointestinal microbiome. Further studies are needed to ascertain additional beneficial effects of other probiotic strains in MetS as well as the mechanisms by which such effects are exerted.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Tenorio-Jimenez et al [ 30 ] report that the 12-week administration of a daily dose of 5 × 10 9 cfu L. reuteri V3401 in capsules was associated with lower levels of inflammation biomarkers, such as TNF-α, IL-6, IL-8 and soluble intercellular adhesion molecule-1 (sICAM-1), in obese adults aged 18 to 65 years with metabolic syndrome, as well as with a reduced risk of CVD. Szulinska et al [ 31 ] also observed that supplementation with the multispecies probiotic Ecologic ® Barrier modified both the functional and biochemical parameters of vascular dysfunction in a group of 81 obese postmenopausal Caucasian women.…”

Section: Probioticsmentioning

confidence: 99%

Probiotics, Prebiotics and Synbiotics—A Promising Strategy in Prevention and Treatment of Cardiovascular Diseases?

Olas

2020

IJMS

View full text Add to dashboard Cite

Recent evidence suggests that probiotics, prebiotics and synbiotics may serve as important dietary components in the prevention (especially) and treatment of cardiovascular diseases (CVD), but the recommendations for their use are often based on brief reports and small clinical studies. This review evaluates the current literature on the correlation between CVD and probiotics, prebiotics and synbiotics. Although research on probiotics, prebiotics and synbiotics has grown exponentially in recent years, particularly regarding the effect of probiotics on CVD, their mechanisms have not been clearly defined. It has been proposed that probiotics lower cholesterol levels, and may protect against CVD, by increasing bile salt synthesis and bile acid deconjugation. Similar effects have also been observed for prebiotics and synbiotics; however, probiotics also appear to have anti-oxidative, anti-platelet and anti-inflammatory properties. Importantly, probiotics not only have demonstrated effects in vitro and in animal models, but also in humans, where supplementation with probiotics decreases the risk factors of CVD. In addition, the properties of commercial probiotics, prebiotics and synbiotics remain undetermined, and further experimental research is needed before these substances can be used in the prevention and treatment of CVD. In particular, well-designed clinical trials are required to determine the influence of probiotics on trimethylamine-N-oxide (TMAO), which is believed to be a marker of CVDs, and to clarify the long-term effects, and action, of probiotic, prebiotic and synbiotic supplementation in combination with drug therapy (for example, aspirin). However, while it cannot be unequivocally stated whether such supplementation yields benefits in the prevention and treatment of CVDs, it is important to note that clinical studies performed to date have not identified any side-effects to use.

show abstract

“…Hence this study will provide valuable scientific information about the effects of this strain in IRS and metabolic syndrome patients. 51…”

Section: Role Of Probioticsmentioning

confidence: 99%

Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review

Kaur¹,

Allahbadia²,

Singh³

2019

AOWMC

View full text Add to dashboard Cite

With obesity growing by leaps and bounds ,being responsible for millions of deaths either directly or indirectly through its complications like type 2 diabetes mellitus (T2M), Metabolic syndrome, various cancers there is need for medical answers to effectively combat it.With the pharmaceutical drugs getting developed and shunted out of market with undesirable side effects directions are being shifted towards more physiological methods using some plant extracts like thylakoids, various anthrocyanins etc to combat Insulin Syndrome (IRS),T2DM similarly attention is being moved to modify gut microbiota with the use of probiotics and synbiotics. Till date most beneficial strains have been developed from Lactobacillus or Bifidobacteria. Although a promising strategy both in animal and human models still human trials have remained few with inconsistent results. Hence need for long term studies with more bacterial strains are desired to ensure Probiotics become an established method of treating obesity .Thus we carried out this review to understand what is the status of use of these Probiotics and synbiotics in human trials in patients having obesity ,T2DM, Hypertension, IRS, nonalcoholic fatty liver disease (NAFLD)and steatohepatitis.

show abstract

Evaluation of the effect of Lactobacillus reuteri V3401 on biomarkers of inflammation, cardiovascular risk and liver steatosis in obese adults with metabolic syndrome: a randomized clinical trial (PROSIR)

Cited by 43 publications

References 22 publications

Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study

Lactobacillus reuteri V3401 Reduces Inflammatory Biomarkers and Modifies the Gastrointestinal Microbiome in Adults with Metabolic Syndrome: The PROSIR Study

Probiotics, Prebiotics and Synbiotics—A Promising Strategy in Prevention and Treatment of Cardiovascular Diseases?

Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review

Contact Info

Product

Resources

About